China (Mainland)
Gefitinib Hydrochloride (CAS: 184475-55-6) CAS NO.439081-18-2
- Min.Order: 100 Gram
- Payment Terms: L/C,T/T,
- Product Details
Keywords
- raw material
- API
- anticancer
Quick Details
- ProName: Gefitinib Hydrochloride (CAS: 184475-5...
- CasNo: 439081-18-2
- Application: Anticancer Raw Material
- DeliveryTime: 7-12 days
- PackAge: Aluminum Foil Bag or Fiber Drum
- Port: Shenzhen
- ProductionCapacity: 100 Metric Ton/Month
- Purity: 99
- Transportation: EMS
- LimitNum: 100 Gram
Superiority
Gefitinib Hydrochloride (CAS: 184475-55-6)
Chemical Information
Product Name Gefitinib hydrochloride
Molecular Formula C22H25Cl2FN4O3
Molecular Weight 483.36
Purity: 99%+
Product Specifications: Pharmaceutical Grade
MOQ(Minimum Order Quantity): 100g
Payment: L/C, T/T,
Shipment: EMS, DHL, FedEx, TNT
Brand: Newbio Pharm-Tech
Description
Gefitinib (ZD-1839, Iressa) is an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor.
Gefitinib inhibited colony formation in soft agar in a dose dependent manner in all cancer cell lines. However, treatment with higher doses resulted in a 2-4-fold increases in apoptosis. Dose-dependent supra-additive increase in growth inhibition was observed when cancer cells were treated with totoxic drugs and Gefitinib. The combined treatment markedly enhanced apoptotic cell death induced by single agent treatment.
Gefitinib treatment of nude mice bearing established human GEO colon cancer xenografts revealed a reversible dose-dependent inhibition of tumor growth because GEO tumors resumed the growth rate of controls at the end of the treatment.
Details
Gefitinib Hydrochloride (CAS: 184475-55-6)
Chemical Information
Product Name Gefitinib hydrochloride
Molecular Formula C22H25Cl2FN4O3
Molecular Weight 483.36
Purity: 99%+
Product Specifications: Pharmaceutical Grade
MOQ(Minimum Order Quantity): 100g
Payment: L/C, T/T,
Shipment: EMS, DHL, FedEx, TNT
Brand: Newbio Pharm-Tech
Description
Gefitinib (ZD-1839, Iressa) is an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor.
Gefitinib inhibited colony formation in soft agar in a dose dependent manner in all cancer cell lines. However, treatment with higher doses resulted in a 2-4-fold increases in apoptosis. Dose-dependent supra-additive increase in growth inhibition was observed when cancer cells were treated with totoxic drugs and Gefitinib. The combined treatment markedly enhanced apoptotic cell death induced by single agent treatment.
Gefitinib treatment of nude mice bearing established human GEO colon cancer xenografts revealed a reversible dose-dependent inhibition of tumor growth because GEO tumors resumed the growth rate of controls at the end of the treatment.